Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0001209191-22-063026

Chief Executive Officer sold 25,000 shares at an average $40.93 ($1,023,290)

  • Chief Executive Officer acquired 25,000 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Kulkarni Samarth Chief Executive Officer 2022-12-28 Option exercise +25,000 $19.12 $478,000 394,111 D: show line 1 in the form
Kulkarni Samarth Chief Executive Officer 2022-12-28 Sale −20,366 $40.81 $831,189 373,745 D: show line 2 in the form
Kulkarni Samarth Chief Executive Officer 2022-12-28 Sale −4,634 $41.45 $192,101 369,111 D: show line 3 in the form
Open-market sales · 25,000 sh · avg $40.93 · $1,023,290

Table II: Derivative

Insider Date Transaction Shares Price Value Owned after D/I
Kulkarni Samarth Chief Executive Officer 2022-12-28 Option exercise · Stock Option (Right to Buy) −25,000 204,582 D: show line 4 in the form
Loading xslF345X03/doc4.xml…